The key COVID-19 findings in genetics, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.
INSIDE THIS MONITOR
34cited sources
4available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY3.5%
Inborn interferon-immunity errors were found in life-threatening COVID-19
The reported proportion of patients with life-threatening COVID-19 who had inborn errors of type I interferon immunity was 3.5%.
The source concerns patients with life-threatening COVID-19. Study design and sampling details are not recorded in this summary, limiting how broadly the proportion can be generalized.
See the evidence
Inborn Errors of IFN Immunity
3.5% Enrichment p < 1x10^-6 in critical COVID-19
Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570.
Some older adults dying from critical COVID-19 had interferon autoantibodies
20%
Neutralizing autoantibodies against type I interferons were reported in 20% of people over 70 who died from critical COVID-19.
The finding is restricted to people over 70 years old who died from critical COVID-19, not to all infections or age groups. Study design is not recorded in this summary.
See the evidence
Of critical COVID-19 deaths in those over 70 have autoantibodies against type I interferons
20%
Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(62):eabl4340.
The 3p21.31 risk locus was associated with higher odds of critical COVID-19 illness, while an OAS1 variant was associated with lower odds of the same outcome.
They were reported in separate studies. The reference groups are not available in this summary, so the odds ratios are not shown and the findings are not a head-to-head comparison.
See the evidence
3p21.31 Risk Locus
OR 2.14 OR 2.14 (95% CI: 1.72-2.67) for critical illness
Severe Covid-19 GWAS Group. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020;383(16):1522-1534.
APOE e4/e4 was associated with COVID-19 hospitalization
In the UK Biobank community cohort, APOE e4/e4 was associated with higher odds of COVID-19 hospitalization.
The reference group is not available in this summary, so the reported odds ratio is not shown. As a community-cohort association, it does not establish causation.
See the evidence
APOE e4/e4 Hospitalization
OR 3.51 OR 3.51 (95% CI: 2.38-5.17) for hospitalization
Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci. 2020;75(11):2231-2232.
OR 0.74OR 0.74 (95% CI: 0.68-0.80) for critical illnessSource [8]
SOURCE 191 finding
Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci. 2020;75(11):2231-2232.
Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(62):eabl4340.
Asano T, Boisson B, Onodi F, et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021;6(62):eabl4348.
Manry J, Bastard P, Gervais A, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci USA. 2022;119(21):e2200413119.
Shelton JF, Shastri AJ, Ye C, et al. Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. Nat Genet. 2021;53(6):801-808.
Zeberg H, Paabo S. A genomic region associated with protection against severe COVID-19 is inherited from Neanderthals. Proc Natl Acad Sci USA. 2021;118(9):e2026309118.
Augusto DG, Murdolo LD, Chatzileontiadou DSM, et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature. 2023;620(7972):128-136.
Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020;6:11.
Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci. 2020;75(11):2231-2232.
Kuo CL, Pilling LC, Atkins JL, et al. ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank. J Gerontol A Biol Sci Med Sci. 2020;75(9):1801-1803.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645.
Casanova JL, Su HC; COVID Human Genetic Effort. A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell. 2020;181(6):1194-1199.
Zhang Q, Cobat A, Bastard P, et al. Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia. J Clin Invest. 2022;132(7):e152474.
Casanova JL, Abel L. From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell. 2022;185(17):3086-3103.
Andreakos E, Abel L, Vinh DC, et al. A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection. Nat Immunol. 2022;23(2):159-164.
Zhang SY, Zhang Q, Casanova JL, Su HC. Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity? Nat Rev Immunol. 2020;20(8):455-456.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.